ZENABIS (ZENA) (ZBISF) EXPLOSION CONTINUES 🚀 скачать в хорошем качестве

ZENABIS (ZENA) (ZBISF) EXPLOSION CONTINUES 🚀

ZENABIS (ZENA) (ZBISF) EXPLOSION CONTINUES 🚀- MAY 20, 2020 - Zenabis Global Inc. (TSX:ZENA.TO) ("Zenabis" or the "Company") is pleased to announce that it has successfully received EU-GMP approval for its Atholville facility and expects to commence commercial export to the European Union in the third quarter of 2020. In addition, the Company is announcing Health Canada approval of additional growing and processing areas at Zenabis Langley. Kevin Coft, Chief Executive Officer of Zenabis stated, "We are very excited to be able to announce that Zenabis, in conjunction with our European Union partners Natrix Sciences Ltd. (formerly Starpharma Ltd. Malta) and ZenPharm Ltd., have received EU-GMP approval. This is a tremendous milestone for the Company as it will allow us to supply bulk dried medicinal cannabis to the European market and allow ZenPharm the supply needed to serve their customers throughout Europe. I would like to extend my thanks to the entire Zenabis team who have made this major achievement possible as well as to our European partners for their continued support in this process. With our extremely competitive cost of cultivation at $0.63 per gram in the first quarter of 2020, we believe we can be incredibly competitive in the export of cannabis to the European Union." Receipt of EU-GMP Approval Zenabis Global Inc. has obtained EU-GMP approval through its Malta-based European partner, ZenPharm Limited. This milestone enables Zenabis to supply the European market with bulk dried medicinal cannabis flower through its ZenPharm joint venture. Zenabis is a 43.5% owner of ZenPharm. ZenPharm is located within an existing EU-GMP facility in Europe managed by the other 43.5% owner of ZenPharm, Natrix Sciences Limited Malta ("Natrix"). ZenPharma is regulated by the Maltese 'Production of Cannabis for Medicinal and Research Purposes Act', which allows for the cultivation, import, processing, and production of cannabis intended for medicinal and research purposes. Zenabis' EU-GMP approval provides ZenPharm with an approved supplier which will allow it to undertake the necessary regulatory requirements in order to achieve its own GMP certification for the packaging and processing of cannabis from the Maltese Medicines Authority. The approval came after an intense 4-day inspection of the facility, which provided ZenPharm with confidence in the Zenabis GMP Quality Management Systems ("QMS") and products. Although this EU-GMP approval only pertains to cannabis supplied to ZenPharm, Zenabis' now proven QMS provides the Company the ability to ship to GMP facilities worldwide for further processing and packaging, subject to the successful completion of QMS audits by other potential international clients. Alan Mayo, Chief Quality & Compliance Officer of Zenabis stated, "Zenabis' achievement demonstrates the commitment that the Company has towards a robust QMS and Quality in general. It is the result of investment by senior leadership and eight months of hard work, dedication, and perseverance by a group of individuals, most of whom had little to no previous GMP experience. I am so proud of the team because they have all come a long way. In less than a year they overcame the challenge of obtaining such a strict pharmaceutical standard like GMP." LEARN TO TRADE JOIN THE RICH TV LIVE TRADING ACADEMY TODAY! JOIN ME DAILY TRADING GOLD, STOCKS, BITCOIN, OIL, FOREX, INDEXES AND SO MUCH MORE https://iM.Academy/corp/cjoin?enrolle... #ZENABIS #RICHTVLIVE #EXPLOSION YOUTUBE SUBSCRIBE -    / richtvlive   www.richtvlive.com Disclaimer Rich TV's company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in Rich TV reports, company profiles, or other investor relations materials and presentations are subject to change. Rich TV and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time. RICH TV LIVE INC. HAS BEEN COMPENSATED $800 FOR MEDIA SERVICES. Stock market investing is inherently risky. Rich TV is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print. We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov.